Fagerhult Group AB header image

Fagerhult Group AB

FAG

Equity

ISIN SE0010048884 / Valor 37094121

NASDAQ Nordic Exchange Stockholm, Equities (2026-04-24)
SEK 22.05-0.23%

Fagerhult Group AB
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Fagerhult Group AB is a Swedish company specializing in the development and production of professional lighting solutions. With a focus on Human Centric Lighting, the company aims to create lighting systems that enhance both physical and mental well-being. Fagerhult leverages scientific research to design products that cater to the needs of various environments, including offices, educational institutions, healthcare facilities, and retail spaces. The company's approach integrates advanced technology and design to improve the quality of light, thereby influencing the comfort and productivity of individuals in illuminated spaces. As a prominent player in the lighting industry, Fagerhult continues to innovate and expand its product offerings to meet the evolving demands of its global clientele.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (21.04.2026):

Fagerhult Group AB — fourth quarter 2025: Order intake was MSEK 1,844 (organic -9.8% y/y) and net sales were MSEK 2,077 (+1.8% reported; -1.6% organic). EBITA before IAC improved to MSEK 215 (margin 10.4% vs 7.8% a year ago) and operating profit before IAC was MSEK 196 (margin 9.4%). Earnings per share before IAC were SEK 0.70 (0.32) and operating cash flow for the quarter was MSEK 345. Items affecting comparability of MSEK -13.1 relate to the phased‑out Seneco‑CityGrid operations; order backlog strengthened to MSEK 1,617.

Order intake and backlog

Fagerhult Group AB (Q4 2025) reported order intake of MSEK 1,844 (2,008), a reported decline but with Infrastructure showing organic growth while Collection drove most of the decrease; Trato TLV and Capelon contributed positively. The total order backlog rose to MSEK 1,617 (1,533).

Sales, margins and cost control

Q4 net sales were MSEK 2,077 (2,040), the strongest quarter of the year; gross margin before IAC held at 38.9%. Selling and administrative expenses fell ~5%, supporting an improved EBITA margin (10.4% vs 7.8% prior year).

Profitability and EPS

EBITA before IAC increased to MSEK 215 in Q4 (up 35% y/y) and operating profit before IAC was MSEK 196. Reported operating profit was MSEK 183 and EPS before IAC for the quarter was SEK 0.70 (0.32); full‑year EPS before IAC was SEK 1.93 and reported EPS SEK 1.80.

Cash flow and financial position

Operating cash flow in Q4 was MSEK 345 (Q4 2024: 356); full‑year operating cash flow was MSEK 740. Net debt increased to MSEK 2,990 (2,261) at year‑end, cash balance MSEK 1,307, and equity/assets ratio was 52.0%.

Business area performance

Collection and Premium delivered the strongest margins in Q4 (Collection operating margin before IAC 13.8%; Premium 12.5%). Professional grew following the Trato TLV acquisition; Infrastructure reported weaker profitability and lower margins.

M&A and strategic developments

Trato TLV and Capelon (acquired and consolidated from Q3) performed in line with plan; Trato contributed MSEK 334.2 in sales since acquisition. Group focus on circularity, smart outdoor (Capelon) and data‑center expansion were highlighted by management.

Items affecting comparability and restructuring

Q4 IAC totalled MSEK -13.1, mainly linked to the decision to phase out Seneco‑CityGrid and related write‑downs (including an ateljé Lyktan inventory write‑down). Full‑year IAC amounted to MSEK -29.8.

Dividend and outlook

The Board proposes a dividend of SEK 1.10 per share for 2025 (prior year 1.40). Management cautioned that Q1 2026 faces a tough comparison to large orders in Q1 2025, though early signals of improvement exist.

Summarized from source with an LLMView Source

Key figures

-49.0%1Y
-65.5%3Y
-58.6%5Y

Performance

33.3%1Y
32.2%3Y
35.7%5Y

Volatility

Market cap

422 M

Market cap (USD)

Daily traded volume (Shares)

354,312

Daily traded volume (Shares)

1 day high/low

54.6 / 53.8

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Netflix Inc
Netflix Inc Netflix Inc Valor: 1413346
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.41%USD 92.44
NVIDIA Corp
NVIDIA Corp NVIDIA Corp Valor: 994529
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%USD 208.27
Advanced Micro Devices Inc
Advanced Micro Devices Inc Advanced Micro Devices Inc Valor: 903491
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
13.91%USD 347.81
Alphabet Inc
Alphabet Inc Alphabet Inc Valor: 29798545
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.35%USD 342.32
SK hynix Inc
SK hynix Inc SK hynix Inc Valor: 18382960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.38%EUR 744.00
Brady Corp
Brady Corp Brady Corp Valor: 913942
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.69%USD 80.70
Marvell Technology Inc
Marvell Technology Inc Marvell Technology Inc Valor: 111229262
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.76%USD 164.31
CDW Corporation
CDW Corporation CDW Corporation Valor: 21034308
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.84%USD 135.32
Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc Biomarin Pharmaceutical Inc Valor: 729021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.48%USD 53.18
Kura Oncology Inc
Kura Oncology Inc Kura Oncology Inc Valor: 28160920
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.11%USD 9.26